Patients with active autoantibody-positive systemic lupus erythematosus (SLE), SLEDAI-2K score ≥6, meeting at least four criteria of the revised ACR classification for SLE, positive for antinuclear antibodies (Hep-2 ANA ≥1:80) and/or anti-double-stranded DNA antibodies (≥30 IU/mL), with a disease duration of at least 6 months. Here, BTG3 is linked to systemic lupus erythematosus.